Now showing items 1-20 of 207

    • Large-scale genotyping identifies 41 new loci associated with breast cancer risk. 

      Michailidou, K; Hall, P; Gonzalez-Neira, A; Ghoussaini, M; Dennis, J; Milne, RL; Schmidt, MK; Chang-Claude, J; Bojesen, SE; Bolla, MK; Wang, Q; Dicks, E; Lee, A; Turnbull, C; Rahman, N; Fletcher, O; Peto, J; Gibson, L; Dos Santos Silva, I; Nevanlinna, H; Muranen, TA; Aittomäki, K; Blomqvist, C; Czene, K; Irwanto, A; Liu, J; Waisfisz, Q; Meijers-Heijboer, H; Adank, M; van der Luijt, RB; Hein, R; Dahmen, N; Beckman, L; Meindl, A; Schmutzler, RK; Müller-Myhsok, B; Lichtner, P; Hopper, JL; Southey, MC; Makalic, E; Schmidt, DF; Uitterlinden, AG; Hofman, A; Hunter, DJ; Chanock, SJ; Vincent, D; Bacot, F; Tessier, DC; Canisius, S; Wessels, LF; Haiman, CA; Shah, M; Luben, R; Brown, J; Luccarini, C; Schoof, N; Humphreys, K; Li, J; Nordestgaard, BG; Nielsen, SF; Flyger, H; Couch, FJ; Wang, X; Vachon, C; Stevens, KN; Lambrechts, D; Moisse, M; Paridaens, R; Christiaens, MR; Rudolph, A; Nickels, S; Flesch-Janys, D; Johnson, N; Aitken, Z; Aaltonen, K; Heikkinen, T; Broeks, A; Veer, LJ; van der Schoot, CE; Guénel, P; Truong, T; Laurent-Puig, P; Menegaux, F; Marme, F; Schneeweiss, A; Sohn, C; Burwinkel, B; Zamora, MP; Perez, JI; Pita, G; Alonso, MR; Cox, A; Brock, IW; Cross, SS; Reed, MW; Sawyer, EJ; Tomlinson, I; Kerin, MJ; Miller, N; Henderson, BE; Schumacher, F; Le Marchand, L; Andrulis, IL; Knight, JA; Glendon, G; Mulligan, AM; Lindblom, A; Margolin, S; Hooning, MJ; Hollestelle, A; van den Ouweland, AM; Jager, A; Bui, QM; Stone, J; Dite, GS; Apicella, C; Tsimiklis, H; Giles, GG; Severi, G; Baglietto, L; Fasching, PA; Haeberle, L; Ekici, AB; Beckmann, MW; Brenner, H; Müller, H; Arndt, V; Stegmaier, C; Swerdlow, A; Ashworth, A; Orr, N; Jones, M; Figueroa, J; Lissowska, J; Brinton, L; Goldberg, MS; Labrèche, F; Dumont, M; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Brauch, H; Hamann, U; Brüning, T; Radice, P; Peterlongo, P; Manoukian, S; Bonanni, B; Devilee, P; Tollenaar, RA; Seynaeve, C; van Asperen, CJ; Jakubowska, A; Lubinski, J; Jaworska, K; Durda, K; Mannermaa, A; Kataja, V; Kosma, VM; Hartikainen, JM; Bogdanova, NV; Antonenkova, NN; Dörk, T; Kristensen, VN; Anton-Culver, H; Slager, S; Toland, AE; Edge, S; Fostira, F; Kang, D; Yoo, KY; Noh, DY; Matsuo, K; Ito, H; Iwata, H; Sueta, A; Wu, AH; Tseng, CC; Van Den Berg, D; Stram, DO; Shu, XO; Lu, W; Gao, YT; Cai, H; Teo, SH; Yip, CH; Phuah, SY; Cornes, BK; Hartman, M; Miao, H; Lim, WY; Sng, JH; Muir, K; Lophatananon, A; Stewart-Brown, S; Siriwanarangsan, P; Shen, CY; Hsiung, CN; Wu, PE; Ding, SL; Sangrajrang, S; Gaborieau, V; Brennan, P; McKay, J; Blot, WJ; Signorello, LB; Cai, Q; Zheng, W; Deming-Halverson, S; Shrubsole, M; Long, J; Simard, J; Garcia-Closas, M; Pharoah, PD; Chenevix-Trench, G; Dunning, AM; Benitez, J; Easton, DF (2013-04)
      Breast cancer is the most common cancer among women. Common variants at 27 loci have been identified as associated with susceptibility to breast cancer, and these account for ∼9% of the familial risk of the disease. We ...
    • Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. 

      Johnson, N; Dudbridge, F; Orr, N; Gibson, L; Jones, ME; Schoemaker, MJ; Folkerd, EJ; Haynes, BP; Hopper, JL; Southey, MC; Dite, GS; Apicella, C; Schmidt, MK; Broeks, A; Van't Veer, LJ; Atsma, F; Muir, K; Lophatananon, A; Fasching, PA; Beckmann, MW; Ekici, AB; Renner, SP; Sawyer, E; Tomlinson, I; Kerin, M; Miller, N; Burwinkel, B; Marme, F; Schneeweiss, A; Sohn, C; Guénel, P; Truong, T; Cordina, E; Menegaux, F; Bojesen, SE; Nordestgaard, BG; Flyger, H; Milne, R; Zamora, MP; Arias Perez, JI; Benitez, J; Bernstein, L; Anton-Culver, H; Ziogas, A; Clarke Dur, C; Brenner, H; Müller, H; Arndt, V; Dieffenbach, AK; Meindl, A; Heil, J; Bartram, CR; Schmutzler, RK; Brauch, H; Justenhoven, C; Ko, YD; Nevanlinna, H; Muranen, TA; Aittomäki, K; Blomqvist, C; Matsuo, K; Dörk, T; Bogdanova, NV; Antonenkova, NN; Lindblom, A; Mannermaa, A; Kataja, V; Kosma, VM; Hartikainen, JM; Chenevix-Trench, G; Beesley, J; Wu, AH; Van den Berg, D; Tseng, CC; Lambrechts, D; Smeets, D; Neven, P; Wildiers, H; Chang-Claude, J; Rudolph, A; Nickels, S; Flesch-Janys, D; Radice, P; Peterlongo, P; Bonanni, B; Pensotti, V; Couch, FJ; Olson, JE; Wang, X; Fredericksen, Z; Pankratz, VS; Giles, GG; Severi, G; Baglietto, L; Haiman, C; Simard, J; Goldberg, MS; Labrèche, F; Dumont, M; Soucy, P; Teo, S; Yip, CH; Phuah, SY; Cornes, BK; Kristensen, VN; Grenaker Alnæs, G; Børresen-Dale, AL; Zheng, W; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Andrulis, IL; Knight, JA; Glendon, G; Mulligan, AM; Devillee, P; Figueroa, J; Chanock, SJ; Lissowska, J; Sherman, ME; Hall, P; Schoof, N; Hooning, M; Hollestelle, A; Oldenburg, RA; Tilanus-Linthorst, M; Liu, J; Cox, A; Brock, IW; Reed, MW; Cross, SS; Blot, W; Signorello, LB; Pharoah, PD; Dunning, AM; Shah, M; Kang, D; Noh, DY; Park, SK; Choi, JY; Hartman, M; Miao, H; Lim, WY; Tang, A; Hamann, U; Försti, A; Rüdiger, T; Ulmer, HU; Jakubowska, A; Lubinski, J; Jaworska-Bieniek, K; Durda, K; Sangrajrang, S; Gaborieau, V; Brennan, P; McKay, J; Slager, S; Toland, AE; Vachon, C; Yannoukakos, D; Shen, CY; Yu, JC; Huang, CS; Hou, MF; González-Neira, A; Tessier, DC; Vincent, D; Bacot, F; Luccarini, C; Dennis, J; Michailidou, K; Bolla, MK; Wang, J; Easton, DF; García-Closas, M; Dowsett, M; Ashworth, A; Swerdlow, AJ; Peto, J; dos Santos Silva, I; Fletcher, O (2014-01)
      We have previously shown that a tag single nucleotide polymorphism (rs10235235), which maps to the CYP3A locus (7q22.1), was associated with a reduction in premenopausal urinary estrone glucuronide levels and a modest ...
    • Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. 

      Natrajan, R; Wilkerson, PM; Marchiò, C; Piscuoglio, S; Ng, CK; Wai, P; Lambros, MB; Samartzis, EP; Dedes, KJ; Frankum, J; Bajrami, I; Kopec, A; Mackay, A; A'hern, R; Fenwick, K; Kozarewa, I; Hakas, J; Mitsopoulos, C; Hardisson, D; Lord, CJ; Kumar-Sinha, C; Ashworth, A; Weigelt, B; Sapino, A; Chinnaiyan, AM; Maher, CA; Reis-Filho, JS (2014-04)
      Micropapillary carcinoma (MPC) is a rare histological special type of breast cancer, characterized by an aggressive clinical behaviour and a pattern of copy number aberrations (CNAs) distinct from that of grade- and oestrogen ...
    • Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress. 

      McDade, SS; Patel, D; Moran, M; Campbell, J; Fenwick, K; Kozarewa, I; Orr, NJ; Lord, CJ; Ashworth, AA; McCance, DJ (2014-06)
      In response to genotoxic stress the TP53 tumour suppressor activates target gene expression to induce cell cycle arrest or apoptosis depending on the extent of DNA damage. These canonical activities can be repressed by ...
    • DAISY: picking synthetic lethals from cancer genomes. 

      Ryan, CJ; Lord, CJ; Ashworth, A (2014-09)
      A better understanding of genetic interactions in cancer might help identify new therapeutic approaches that exploit the concept of synthetic lethality. Ruppin and colleagues have developed a new computational method, ...
    • The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling. 

      Rajan, N; Elliott, RJ; Smith, A; Sinclair, N; Swift, S; Lord, CJ; Ashworth, A (2014-12)
      CYLD, an ubiquitin hydrolase, has an expanding repertoire of regulatory roles in cell signalling and is dysregulated in a number of cancers. To dissect CYLD function we used a proteomics approach to identify CYLD interacting ...
    • Genome-wide homozygosity signature and risk of Hodgkin lymphoma. 

      Sud, A; Cooke, R; Swerdlow, AJ; Houlston, RS (2015-01)
      Recent studies have reported that regions of homozygosity (ROH) in the genome are detectable in outbred populations and can be associated with an increased risk of malignancy. To examine whether homozygosity is associated ...
    • JAMA Oncology 

      Dowsett, Mitch; Buus, Richard (2015-04-01)
    • Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. 

      Conti, A; Majorini, MT; Elliott, R; Ashworth, A; Lord, CJ; Cancelliere, C; Bardelli, A; Seneci, P; Walczak, H; Delia, D; Lecis, D (2015-05)
      KRAS is mutated in about 20-25% of all human cancers and especially in pancreatic, lung and colorectal tumors. Oncogenic KRAS stimulates several pro-survival pathways, but it also triggers the trans-activation of pro-apoptotic ...
    • Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity. 

      Frankum, J; Moudry, P; Brough, R; Hodny, Z; Ashworth, A; Bartek, J; Lord, CJ (2015-05)
      Based on a series of basic, preclinical and clinical studies, the Poly (ADP-ribose) Polymerase 1 (PARP1) inhibitor, olaparib, has recently been approved for use in ovarian cancer patients with BRCA1 or BRCA2 mutations. By ...
    • TransHERA: The cell cycle regulator p27 predicts benefit from trastuzumab treatment in HER2-positive early breast cancer patients treated within the HERA trial 

      Filipits, M; Gnant, M; Dafni, U; Polydoropoulou, V; Hills, MJ; Leyland-Jones, B; Piccart-Gebhart, M; Dowsett, M (2015-05-01)
    • Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. 

      Garcia-Murillas, I; Schiavon, G; Weigelt, B; Ng, C; Hrebien, S; Cutts, RJ; Cheang, M; Osin, P; Nerurkar, A; Kozarewa, I; Garrido, JA; Dowsett, M; Reis-Filho, JS; Smith, IE; Turner, NC (2015-08)
      The identification of early-stage breast cancer patients at high risk of relapse would allow tailoring of adjuvant therapy approaches. We assessed whether analysis of circulating tumor DNA (ctDNA) in plasma can be used to ...
    • Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer. 

      Hrebien, S; O'Leary, B; Beaney, M; Schiavon, G; Fribbens, C; Bhambra, A; Johnson, R; Garcia-Murillas, I; Turner, N (2016)
      Circulating tumor DNA (ctDNA) analysis has the potential to allow non-invasive analysis of tumor mutations in advanced cancer. In this study we assessed the reproducibility of digital PCR (dPCR) assays of circulating tumor ...
    • Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. 

      Costa-Cabral, S; Brough, R; Konde, A; Aarts, M; Campbell, J; Marinari, E; Riffell, J; Bardelli, A; Torrance, C; Lord, CJ; Ashworth, A (2016-01)
    • Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. 

      López-Knowles, E; Gao, Q; Cheang, MC; Morden, J; Parker, J; Martin, LA; Pinhel, I; McNeill, F; Hills, M; Detre, S; Afentakis, M; Zabaglo, L; Dodson, A; Skene, A; Holcombe, C; Robertson, J; Smith, I; Bliss, JM; Dowsett, M (2016-01)
      Gene expression is widely used for the characterisation of breast cancers. Variability due to tissue heterogeneity or measurement error or systematic change due to peri-surgical procedures can affect measurements but is ...
    • Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. 

      Simigdala, N; Gao, Q; Pancholi, S; Roberg-Larsen, H; Zvelebil, M; Ribas, R; Folkerd, E; Thompson, A; Bhamra, A; Dowsett, M; Martin, LA (2016-01)
      Therapies targeting estrogenic stimulation in estrogen receptor-positive (ER+) breast cancer (BC) reduce mortality, but resistance remains a major clinical problem. Molecular studies have shown few high-frequency mutations ...
    • Impact of type of full-field digital image on mammographic density assessment and breast cancer risk estimation: a case-control study. 

      Busana, MC; Eng, A; Denholm, R; Dowsett, M; Vinnicombe, S; Allen, S; Dos-Santos-Silva, I (2016-01)
      Full-field digital mammography, which is gradually being introduced in most clinical and screening settings, produces two types of images: raw and processed. However, the extent to which mammographic density measurements, ...
    • Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. 

      Couch, FJ; Kuchenbaecker, KB; Michailidou, K; Mendoza-Fandino, GA; Nord, S; Lilyquist, J; Olswold, C; Hallberg, E; Agata, S; Ahsan, H; Aittomäki, K; Ambrosone, C; Andrulis, IL; Anton-Culver, H; Arndt, V; Arun, BK; Arver, B; Barile, M; Barkardottir, RB; Barrowdale, D; Beckmann, L; Beckmann, MW; Benitez, J; Blank, SV; Blomqvist, C; Bogdanova, NV; Bojesen, SE; Bolla, MK; Bonanni, B; Brauch, H; Brenner, H; Burwinkel, B; Buys, SS; Caldes, T; Caligo, MA; Canzian, F; Carpenter, J; Chang-Claude, J; Chanock, SJ; Chung, WK; Claes, KB; Cox, A; Cross, SS; Cunningham, JM; Czene, K; Daly, MB; Damiola, F; Darabi, H; de la Hoya, M; Devilee, P; Diez, O; Ding, YC; Dolcetti, R; Domchek, SM; Dorfling, CM; Dos-Santos-Silva, I; Dumont, M; Dunning, AM; Eccles, DM; Ehrencrona, H; Ekici, AB; Eliassen, H; Ellis, S; Fasching, PA; Figueroa, J; Flesch-Janys, D; Försti, A; Fostira, F; Foulkes, WD; Friebel, T; Friedman, E; Frost, D; Gabrielson, M; Gammon, MD; Ganz, PA; Gapstur, SM; Garber, J; Gaudet, MM; Gayther, SA; Gerdes, AM; Ghoussaini, M; Giles, GG; Glendon, G; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Greene, MH; Gronwald, J; Guénel, P; Gunter, M; Haeberle, L; Haiman, CA; Hamann, U; Hansen, TV; Hart, S; Healey, S; Heikkinen, T; Henderson, BE; Herzog, J; Hogervorst, FB; Hollestelle, A; Hooning, MJ; Hoover, RN; Hopper, JL; Humphreys, K; Hunter, DJ; Huzarski, T; Imyanitov, EN; Isaacs, C; Jakubowska, A; James, P; Janavicius, R; Jensen, UB; John, EM; Jones, M; Kabisch, M; Kar, S; Karlan, BY; Khan, S; Khaw, KT; Kibriya, MG; Knight, JA; Ko, YD; Konstantopoulou, I; Kosma, VM; Kristensen, V; Kwong, A; Laitman, Y; Lambrechts, D; Lazaro, C; Lee, E; Le Marchand, L; Lester, J; Lindblom, A; Lindor, N; Lindstrom, S; Liu, J; Long, J; Lubinski, J; Mai, PL; Makalic, E; Malone, KE; Mannermaa, A; Manoukian, S; Margolin, S; Marme, F; Martens, JW; McGuffog, L; Meindl, A; Miller, A; Milne, RL; Miron, P; Montagna, M; Mazoyer, S; Mulligan, AM; Muranen, TA; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Nordestgaard, BG; Nussbaum, RL; Offit, K; Olah, E; Olopade, OI; Olson, JE; Osorio, A; Park, SK; Peeters, PH; Peissel, B; Peterlongo, P; Peto, J; Phelan, CM; Pilarski, R; Poppe, B; Pylkäs, K; Radice, P; Rahman, N; Rantala, J; Rappaport, C; Rennert, G; Richardson, A; Robson, M; Romieu, I; Rudolph, A; Rutgers, EJ; Sanchez, MJ; Santella, RM; Sawyer, EJ; Schmidt, DF; Schmidt, MK; Schmutzler, RK; Schumacher, F; Scott, R; Senter, L; Sharma, P; Simard, J; Singer, CF; Sinilnikova, OM; Soucy, P; Southey, M; Steinemann, D; Stenmark-Askmalm, M; Stoppa-Lyonnet, D; Swerdlow, A; Szabo, CI; Tamimi, R; Tapper, W; Teixeira, MR; Teo, SH; Terry, MB; Thomassen, M; Thompson, D; Tihomirova, L; Toland, AE; Tollenaar, RA; Tomlinson, I; Truong, T; Tsimiklis, H; Teulé, A; Tumino, R; Tung, N; Turnbull, C; Ursin, G; van Deurzen, CH; van Rensburg, EJ; Varon-Mateeva, R; Wang, Z; Wang-Gohrke, S; Weiderpass, E; Weitzel, JN; Whittemore, A; Wildiers, H; Winqvist, R; Yang, XR; Yannoukakos, D; Yao, S; Zamora, MP; Zheng, W; Hall, P; Kraft, P; Vachon, C; Slager, S; Chenevix-Trench, G; Pharoah, PD; Monteiro, AA; García-Closas, M; Easton, DF; Antoniou, AC (2016-01)
      Common variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (P<5 × 10(-8)) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast ...
    • Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation. 

      Guest, SK; Ribas, R; Pancholi, S; Nikitorowicz-Buniak, J; Simigdala, N; Dowsett, M; Johnston, SR; Martin, LA (2016-01)
      Despite the effectiveness of endocrine therapies in estrogen receptor positive (ER+) breast cancer, approximately 40% of patients relapse. Previously, we identified the Focal-adhesion kinase canonical pathway as a major ...
    • RAD51B in Familial Breast Cancer. 

      Pelttari, LM; Khan, S; Vuorela, M; Kiiski, JI; Vilske, S; Nevanlinna, V; Ranta, S; Schleutker, J; Winqvist, R; Kallioniemi, A; Dörk, T; Bogdanova, NV; Figueroa, J; Pharoah, PD; Schmidt, MK; Dunning, AM; García-Closas, M; Bolla, MK; Dennis, J; Michailidou, K; Wang, Q; Hopper, JL; Southey, MC; Rosenberg, EH; Fasching, PA; Beckmann, MW; Peto, J; Dos-Santos-Silva, I; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Surowy, H; Guénel, P; Truong, T; Bojesen, SE; Nordestgaard, BG; Benitez, J; González-Neira, A; Neuhausen, SL; Anton-Culver, H; Brenner, H; Arndt, V; Meindl, A; Schmutzler, RK; Brauch, H; Brüning, T; Lindblom, A; Margolin, S; Mannermaa, A; Hartikainen, JM; Chenevix-Trench, G; Van Dyck, L; Janssen, H; Chang-Claude, J; Rudolph, A; Radice, P; Peterlongo, P; Hallberg, E; Olson, JE; Giles, GG; Milne, RL; Haiman, CA; Schumacher, F; Simard, J; Dumont, M; Kristensen, V; Borresen-Dale, AL; Zheng, W; Beeghly-Fadiel, A; Grip, M; Andrulis, IL; Glendon, G; Devilee, P; Seynaeve, C; Hooning, MJ; Collée, M; Cox, A; Cross, SS; Shah, M; Luben, RN; Hamann, U; Torres, D; Jakubowska, A; Lubinski, J; Couch, FJ; Yannoukakos, D; Orr, N; Swerdlow, A; Darabi, H; Li, J; Czene, K; Hall, P; Easton, DF; Mattson, J; Blomqvist, C; Aittomäki, K; Nevanlinna, H (2016-01)
      Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 with the risk of female breast cancer and rs1314913 with the risk of male breast cancer. The aim of this study ...